DrugGenEx-Net: a Novel Computational Platform for Systems Pharmacology and Gene Expression-based Drug Repurposing
Overview
Authors
Affiliations
Background: The targeting of disease-related proteins is important for drug discovery, and yet target-based discovery has not been fruitful. Contextualizing overall biological processes is critical to formulating successful drug-disease hypotheses. Network pharmacology helps to overcome target-based bottlenecks through systems biology analytics, such as protein-protein interaction (PPI) networks and pathway regulation.
Results: We present a systems polypharmacology platform entitled DrugGenEx-Net (DGE-NET). DGE-NET predicts empirical drug-target (DT) interactions, integrates interaction pairs into a multi-tiered network analysis, and ultimately predicts disease-specific drug polypharmacology through systems-based gene expression analysis. Incorporation of established biological network annotations for protein target-disease, -signaling pathway, -molecular function, and protein-protein interactions enhances predicted DT effects on disease pathophysiology. Over 50 drug-disease and 100 drug-pathway predictions are validated. For example, the predicted systems pharmacology of the cholesterol-lowering agent ezetimibe corroborates its potential carcinogenicity. When disease-specific gene expression analysis is integrated, DGE-NET prioritizes known therapeutics/experimental drugs as well as their contra-indications. Proof-of-concept is established for immune-related rheumatoid arthritis and inflammatory bowel disease, as well as neuro-degenerative Alzheimer's and Parkinson's diseases.
Conclusions: DGE-NET is a novel computational method that predicting drug therapeutic and counter-therapeutic indications by uniquely integrating systems pharmacology with gene expression analysis. DGE-NET correctly predicts various drug-disease indications by linking the biological activity of drugs and diseases at multiple tiers of biological action, and is therefore a useful approach to identifying drug candidates for re-purposing.
Drug repurposing for Alzheimer's disease from 2012-2022-a 10-year literature review.
Grabowska M, Huang A, Wen Z, Li B, Wei W Front Pharmacol. 2023; 14:1257700.
PMID: 37745051 PMC: 10512468. DOI: 10.3389/fphar.2023.1257700.
Transcriptomics for Clinical and Experimental Biology Research: Hang on a Seq.
Stokes T, Cen H, Kapranov P, Gallagher I, Pitsillides A, Volmar C Adv Genet (Hoboken). 2023; 4(2):2200024.
PMID: 37288167 PMC: 10242409. DOI: 10.1002/ggn2.202200024.
Roque C, Chung K, McCurdy E, Jagannathan R, Randolph L, Herline-Killian K Sci Adv. 2023; 9(9):eadd2671.
PMID: 36867706 PMC: 9984184. DOI: 10.1126/sciadv.add2671.
Issa N, Wathieu H, Glasgow E, Peran I, Parasido E, Li T Ecotoxicol Environ Saf. 2022; 233:113330.
PMID: 35189517 PMC: 10202418. DOI: 10.1016/j.ecoenv.2022.113330.
Applied machine learning in Alzheimer's disease research: omics, imaging, and clinical data.
Li Z, Jiang X, Wang Y, Kim Y Emerg Top Life Sci. 2021; 5(6):765-777.
PMID: 34881778 PMC: 8786302. DOI: 10.1042/ETLS20210249.